Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.
Mol Imaging. 2010 Dec;9(6):291-310.
Because of their large size compared to small molecules and their multifunctionality, nanoparticles (NPs) hold promise as biomedical imaging, diagnostic, and theragnostic agents. However, the key to their success hinges on a detailed understanding of their behavior after administration into the body. NP biodistribution, target binding, and clearance are complex functions of their physicochemical properties in serum, which include hydrodynamic diameter, solubility, stability, shape and flexibility, surface charge, composition, and formulation. Moreover, many materials used to construct NPs have real or potential toxicity or may interfere with other medical tests. In this review, we discuss the design considerations that mediate NP behavior in the body and the fundamental principles that govern clinical translation. By analyzing those nanomaterials that have already received regulatory approval, most of which are actually therapeutic agents, we attempt to predict which types of NPs hold potential as diagnostic agents for biomedical imaging. Finally, using quantum dots as an example, we provide a framework for deciding whether an NP-based agent is the best choice for a particular clinical application.
由于纳米颗粒(NPs)相对于小分子而言体积较大且多功能,因此有望成为生物医学成像、诊断和治疗诊断试剂。然而,其成功的关键在于详细了解其在体内给药后的行为。NPs 的生物分布、靶结合和清除是其在血清中的物理化学性质的复杂功能,这些性质包括水动力直径、溶解度、稳定性、形状和柔韧性、表面电荷、组成和配方。此外,许多用于构建 NPs 的材料具有实际或潜在的毒性,或者可能会干扰其他医学检测。在这篇综述中,我们讨论了介导 NPs 在体内行为的设计考虑因素以及指导临床转化的基本原理。通过分析已经获得监管批准的纳米材料,其中大多数实际上是治疗剂,我们试图预测哪种类型的 NPs 有可能成为生物医学成像的诊断试剂。最后,我们以量子点为例,提供了一个用于判断基于 NP 的试剂是否是特定临床应用的最佳选择的框架。